Video

Mark Freedman From University of Ottawa: Interferon Still a Viable Option for Multiple Sclerosis

Author(s):

While newer medications are constantly being developed for multiple sclerosis one of the original options may still be the best for some patients.

While newer medications are constantly being developed for multiple sclerosis one of the original options may still be the best for some patients.

Mark Freedman, HBSc, MSc, MD, from the University of Ottawa, discussed what he said some have described as a "defunct" treatment option during the annual ACTRIMS conference in New Orleans. There may be a rush to go with the newest and the most innovative medications as soon as they hit the market but Freedman said interferon is an option that doctors know works and has a decades long track record to back up its success as well as identify potential adverse events.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.